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Abstract 
The rise of diabetes incidence in Nigeria enhances the use of popular remedies which 
may interact with conventional therapies. The aqueous extracts of 27 popular Nigerian 
‘antidiabetic’ plants were tested for their in vitro effects on glutathione levels within 
HepG2 cells, P-glycoprotein (P-gp) mediated Rh-123 efflux activity in Caco2 
vincristine-resistant cells and modulation of glibenclamide transport in Caco-2 
monolayers. The extract from Ximenia americana significantly depleted intracellular 
glutathione at 100 µg/mL similarly to the reference buthionine sulphoximine (p<0.05). 
Other ten extracts raised glutathione levels. Eight extracts inhibiting P-gp efflux in a 
concentration-dependent manner (p<0.01) were selected for further evaluation in a bi-
directional transport model across Caco-2 monolayers: Annona senegalensis, Bridellia 
ferruginea, Cassytha filiformis, Daniellia ogea, Khaya ivorensis, Syzygium guineense, 
Terminalia avicennioides, and Ximenia Americana. When interferences in paracellular 
transport were discarded, only three of them may be modulating the efflux ratio of 
glibenclamide (Efflux ratio 2.65 ± 0.13) in the same manner the reference drug 
Verapamil (Efflux ratio 1.14 ± 0.25; P<0.01) does:  Syzygium guineense (Efflux ratio 
1.70 ± 0.23; P<0.01), Terminalia avicennioides (Efflux ratio 1.80 ± 0.25; P<0.05) and 
Ximenia Americana (Efflux ratio 1.66 ± 0.10; P<0.01). HPLC-UV analyses for P-gp 
inhibitors in these extracts revealed several phenolic compounds such as rutin, gallic acid 
and ellagic acid reported to decrease P-gp expression and/or directly modify its function. 
In conclusion, some popular herbal medicines used by Nigerian diabetic patients are 
here shown to potentially affect glibenclamide absorption at concentrations that could 
be reached in the intestinal tract. 
Keywords: Diabetes, Drug Interactions, P-glycoprotein, Glyburide, 
Glutathione, Syzygium guineense. Terminalia avicennioides, Ximenia Americana. 
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Introduction 
The use of herbal medicines as one of the aspects of traditional medicine practice is 
increasingly being promoted in developing countries as a means of meeting the unmet 
healthcare needs of the population [1]. As a result, many diabetic patients utilize herbal 
medicines as supplementation to their conventional medicines for their disease 
management. The chronic nature of the treatment for diabetes increases the risk of 
potential Herb-Drug Interactions (HDI) between traditional herbal products and 
prescription medicines notably those controlling blood sugar levels [2]. The 
implications of inhibition of drug absorption can have far-reaching effects, with 
hypoglycaemia being potentially fatal [3]. Thus, there is a need to anticipate such 
potential HDIs, which would otherwise present a further burden on the patient and on 
the country’s healthcare system.  
In order to forestall this, adequate information about the pharmacological and 
toxicological profile of these herbal medicines and how these would in turn affect the 
bioavailability of the co-administered drug is required. We previously reviewed and 
discussed the evidence behind more than 100 plants with ethnopharmacological records 
for their use in the management of diabetes in Nigeria [4], as well as their impact in 
Nigerian patients [5]. Only forty of the plants assessed have records of in vitro 
interactions with known pharmacokinetic parameters, with some interacting with more 
than one parameter. Morinda lucida has been shown to inhibit P- glycoprotein (P-gp) 
efflux as well as cytochrome and GST enzymes. More importantly, some of these 
identified plants -Vernonia amygdalina, Mangifera indica and Phyllanthus amarus- are 
currently being co-administered by diabetic patients with prescription drugs with 
overlapping pharmacokinetic effects as identified during the field work [5]. These 
brings to immediate attention those plants that would require further evaluation to 
confirm the presence or not of clinically relevant HDIs. In this work we will try to fill 
the gap by studying the effect of 27 plants on glutathione intracellular levels and P-gp 
efflux activity. 
In the small intestine, interactions with P-gp are important in determining the 
bioavailability and subsequent oral dosing of the drug, either singly or in combination 
with other drugs.  It also helps in identifying drugs that would be contraindicated, since 
4 
a co-administration may bring about altered plasma concentration levels [6]. In both the 
intestine and the liver, conjugation with glutathione is a fundamental part of the 
metabolism of xenobiotics. When the conjugate glutathione-xenobiotic is formed, it 
becomes the substrate for further metabolic reactions with the final product being 
eliminated from the organism. ‘Too low’ plasma levels could result in decreased 
efficacy or no efficacy, while ‘too high’ levels could result in increased toxicity. Various 
herbal medicines have been shown to interact with P-gp, some of which have been 
attributed to the presence of identified secondary plant metabolites in the plant. One of 
such plant metabolites is curcumin, a natural polyphenol found in the rhizomes of 
Curcuma longa, which are used by hundreds of millions of people all over the World 
every day both as food and as a medicine [7]. 
A number of studies have identified glibenclamide as a substrate and inhibitor of P-gp 
in P- gp overexpressing cell lines [8,9]. In line with this, clarithromycin (a known P-gp 
inhibitor) altered the pharmacokinetics of glibenclamide in healthy subjects by 
increasing its peak plasma concentration (Cmax) and area under the plasma 
concentration-time curve (AUC) by 1.25 and 1.35 fold respectively [10]; indicating a 
potential risk of P-gp induced DDI. This transport study was therefore carried out to 
assess the potential for HDIs between the extracts previously identified as P-gp 
modulators in the Rh-123 efflux assay and glibenclamide when both are co-
administered by diabetic patients. 
To contribute to the prediction of potential pharmacokinetic herb-drug interactions in 
Nigeria, we here evaluated for the first time the possible interaction of a number of 
these medicinal plants used in diabetes management on the efflux activity of P- 
glycoprotein with further evaluation of its effects on the transport of glibenclamide, 
itself a P-gp substrate- one of the most commonly administered drugs to diabetic 
patients. 
Results and Discussion 
The extracts were obtained in the field and extracted according to popular recipes. The 
conditioned extracts were chromatographed against a set of 13 pyhtochemicals. A file 
containing all the chromatograms has been provided as Supporting information. Our 
extraction protocol mimics the quantities of a typical quantity per cup: some 10 grams 
of plant material in 200 mL water. According Table 1, average yield of the extracts is 
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12% w/w, thus implying some 1.2 g of extractable matter. Therefore a fasting patient 
could ingest a solution of 1.200mg/200ml = 0.6 mg/mL or 600 µg/mL, in direct 
contact to the intestinal epithelium. This is equivalent to six times our 
maximum tested concentration (100 µg/mL). 
The use of HepG2 cells as a proxy for primary hepatocytes is well-established despite 
several limitations such as a low expression of CYP enzymes which is reversible upon 
re-expression of the Nuclear factor C/EBPα [11]. However, HepG2 still conserve 
glutathione metabolism providing with an accessible in vitro cell model for both 
physiological and pathological models [12]. Our results on the effects of the plant 
extracts on the intracellular content of glutathione are shown in Figure 1. Only the 
extract obtained from Ximenia americana significantly depleted intracellular 
glutathione at 100 µg/mL similarly to 10 µM of the reference buthionine sulphoximine 
(p<0.01). Interestingly, ten extracts significantly raised glutathione levels including 
Anthocliesta djalonensis, Aristolochia repens, Bridelia ferruginea, Cassytha filiformis, 
Isoberlinia doka, Khaya senegalensis, Moringa oleifera, Mondia whitei, Rauvolfia 
vomitoria and Tamarindus indica. The latest could be regarded as a protective effect, 
but may in turn have the result of favouring conjugation in Phase 2 thus rendering 
inactive drugs which detoxification heavily relies on this pathway, such 
as acetaminophen. However, we have to bear in mind that if the plant extracts are 
also inhibitors of key enzymes such Glutathione transferase (GST), then any 
increase of glutathione levels would not be effectively translated into conjugation of 
xenobiotics.  This is a limitation in the interpretation of any clinical implication of the 
results from this assay.  
To identify extracts that may modulate P-gp efflux activity, Caco-2 Vincristine-
Resistant (overexpressing P-gp) were co-incubated with Rh-123 and 100 µg/mL of each 
extract for two hours.  Cells were also incubated with 20 µM verapamil as positive 
control while cells with only Rh-123 served as negative control. The intracellular Rh-
123 fluorescence determined after cell lysis. The percentage change in Rh-123 
fluorescence relative to the fluorescence in the control cells after co-incubation with the 
extracts is shown in Figure 2.  
Eight extracts- Annona senegalensis, Bridelia ferruginea, Cassytha filiformis, 
Daniellia ogea, Khaya ivorensis, Syzygium guineense, Terminalia avicennioides and 
6 
Ximenia americana produced a highly significant elevation (P<0.01) in the intracellular 
accumulation of Rh-123 (Figure 2). Their effects are largely concentration-dependent 
as shown in Figure 3. These results may suggest that these plant extracts are acting as 
drug transport modulators via inhibition of the P-gp efflux. However, the uptake of 
Rh-123 into cells can be either a passive or an active process: OATP1A2-
mediated facilitated transport is predominant at low single digit µM concentrations, 
whilst double digit µM concentrations occur via micelle-mediated passive diffusion. 
This and cell line-dependent factors may influence the interpretation of transport 
assays [13]. 
The highest observed inhibitory effect was exerted by Bridelia ferruginea followed by 
Ximenia americana and Khaya ivorensis with 3- to 2- fold that produced by the 
positive control verapamil at 20 µM. Such high changes in intracellular Rh- 123 
accumulation by plant extracts are not uncommon. A similar study carried out with 
the stem bark extract of Mangifera indica produced a 1000% increase in 
intracellular Rh-123 accumulation [11]. As shown in Figure 3, the extracts 
produced a concentration-dependent inhibition of P-gp activity, which might 
indicate a certain degree of specificity in their effect. 
HPLC-UV-PDA analyses for ubiquitous P-gp modulators pointed out that the 
activities of Bridelia ferruginea, and Ximenia americana may be explained at least in 
part by the presence of gallic acid. Gallic acid, besides its well- known antioxidant 
activity, can decrease P-gp expression in HK-2 cells [15] and directly modify its 
function on KB-C2 cells [16]. Syzygium guineense and  Annona senegalensis contain 
rutin and ellagic acid, respectively. Rutin and Ellagic acid, have been also 
described as inhibiting efflux pumps and transporters [17–19].  
To evaluate the effects of the selected P-gp inhibitory extracts on the permeability and 
transport of glibenclamide, three parameters were measured: the TEER value before 
and after the transport experiment, the apparent permeability of the paracellular 
marker FD4 across the Caco-2 monolayers and the apparent permeability of 
glibenclamide across the monolayer. The first two measurements were carried out to 
monitor the effect of the extracts on the integrity of the monolayer, while the last 
measurement was for direct estimation of its effect on glibenclamide transport (Table 
2). 
The maturation of tight junctions during differentiation of Caco-2 cells grown in vitro 
is a crucial factor for its use as a model for intestinal drug permeability and transport. 
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Various studies recommend the use of cells that have been grown in a monolayer for at 
least 21 days for transport experiments based on evidence of morphological changes 
related to cellular differentiation [12]. A decrease in the permeability of the cell 
monolayer is an indicator for tight junction maturation and can be monitored by 
measuring the TEER values of the monolayer over several days [13]. 
In bi-directional transport experiments, P-gp substrates are confirmed by comparing 
apparent permeability in the apical to basolateral (AP-BL) direction with that in the 
basolateral to apical (BL-AP) direction. Compounds with efflux ratio (Papp (BL-
AP)/Papp (AP-BL) greater than 2 to 3 are typically identified as P-gp substrates [14]. 
This study obtained an average efflux ratio of 2.65 ± 0.13 for glibenclamide, thereby 
confirming it as a P-gp substrate (Table 4.7). As far as we know, this is the first time 
glibenclamide is experimentally confirmed as a P-gp substrate in such bi-directional 
transport model. 
A typical P-gp inhibitor would decrease the efflux of the P-gp substrate, thereby 
decreasing the permeability in the efflux direction or secretory permeability or Papp 
(BL-AP) while increasing the absorptive permeability Papp (AP-BL). This change in 
the Papp of both directions would ultimately result in a decreased efflux ratio. As shown 
in table 3, verapamil the control P-gp inhibitor decreased the Papp (BL-AP) of 
glibenclamide from 6.3×10-5 cm/s to 4.62×10-5 cm/s and increased its Papp (AP-
BL) from 2.65×10-5 cm/s to 4.03×10-5 cm/s, thereby decreasing its efflux ratio from
2.65 to 1.14 (P<0.01). 
Interferences in paracellular transport (denoted by a significant Papp FD4) were 
suspected for Cassytha filiformis and Khaya ivorensis. With those discarded, only three 
of them may be clearly modulating the efflux ratio of glibenclamide in the same manner 
the reference drug Verapamil (Efflux ratio 1.14 ± 0.25; P<0.01) does:  Syzygium 
guineense (Efflux ratio 1.70 ± 0.23; P<0.01), Terminalia avicennioides (Efflux ratio 
1.80 ± 0.25; P<0.05) and Ximenia americana (Efflux ratio 1.66 ± 0.10; P<0.01). 
Contrary to expectation that all the active extracts in the Rh-123 efflux assay would 
interfere with the transport of glibenclamide, only two of them – Syzygium guineense 
and Terminalia avicennioides - produced a similar effect as verapamil in this model as 
seen in Table 2. They both increased the Papp (AP-BL) of glibenclamide to 3.38 and 
3.06×10-5 cm/s respectively and decreased the Papp (AP-BL) of glibenclamide to 5.7 
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and 5.56×10-5 cm/s respectively. Aside for its possible P-gp inhibitory effect, 
Terminalia avicennioides also produced a greater effect on membrane permeability 
with possible opening of tight junctions, evidenced by its increased Papp (AP-BL) 
transport of FD4 and a higher change in TEER values compared to glibenclamide alone. 
This could in turn contribute to the increased Papp (AP-BL) seen with glibenclamide. 
The reasons for these conflicting results between the Rh-123 efflux assay and the 
bidirectional transport assay for the other extracts might be due to other unidentified 
interacting effects of the extracts. For instance, although Khaya ivorensis increased the 
Papp (AP-BL) of glibenclamide from 2.65– 5.6×10-5 cm/s, the Papp (BL-AP) also 
increased very slightly from 6.13×10-5 cm/s to 6.6×10-5 cm/s. One possible 
suggestion for the increased effect of Khaya ivorensis on glibenclamide transport in 
the absorptive direction might be due to an effect on membrane permeability given the 
higher change in TEER values but these would need to be clarified. These studies 
have however highlighted the possibility of obtaining false positives in the 
identification of P-gp modulators simply based on in vitro intracellular accumulation 
assays. 
Although the clinical implication of the P-gp inhibitory effect of these two extracts on 
glibenclamide bioavailability can only best be assessed in an in vivo study in humans, 
it may be suggested that its effects on glibenclamide bioavailability is likely to be 
minimal. This is because the extracts only caused a slight increase in the absorptive 
apparent permeability of glibenclamide. With a borderline efflux ratio of 2.38, 
glibenclamide would only be considered as a moderate P-gp substrate such that the P-
gp inhibition of the extracts did not bring about a significant change in its apparent 
permeability. As this is the first time the identity of glibenclamide as a P-gp substrate 
based on a bi-directional transport model is being carried out, a comparison of the 
effect of well-known P-gp inhibitors on the Papp of glibenclamide alongside 
other P-gp substrates with higher efflux ratios would therefore need to be carried out 
to ensure a thorough assessment. 
Finally, some of the extracts did not exhibit the expected characteristics of P-gp 
modulators either in the P-gp screening or the bi-directional transport, they could still 
modulate intestinal drug absorption through their effects on tight junctions. Further 
experiments would be needed to confirm this especially as decrease in TEER values 
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have been identified as a cytotoxic mechanism that could potentially affect intestinal 
drug absorption [19]. 
Glutathione levels may affect/modulate P-gp (a MRP1 protein) mediated transport in 
this model is a very complex manner. On the one hand, it has been reported that 
MRP1 transports vincristine in an ATP- and GSH-dependent manner [24], so in 
principle extracts increasing GSH will positively influence efflux activity. On the 
other hand, GSH conjugates, GSH and GSH disulfide are actively transported across 
membranes using the same MRP1 transport protein, which may itself compete with 
xenobotic efflux [25]. Ballatori and co-workers affirm that this high background rate 
of GSH transport is a major confounding variable in GSH transport measurements, 
and severely limits the choice of cells with which this process can be studied. To 
further complicate matters, GSH tself facilitates membrane transport of endo- 
and xenobiotics by stimulating MRP-mediated transport [26]. 
We may conclude that more in vivo experiments are warranted to ascertain the effect of 
the here reported active herbals. In the meantime, we suggest that diabetic patients on 
glibenclamide, the second most prescribed anti-diabetic drug in Nigeria, using herbal 
remedies containing Syzygium guineense Terminalia avicennioides and Ximenia 
americana should be specially monitored by healthcare professionals, for these herbals 
modulated P-gp efflux in our models at concentrations that could be reached in the 
intestinal tract. We also suggest caution to those regularly using Ximenia americana if 
they need to use drugs which detoxification is dependent on glutathione. 
Material and Methods 
Chemicals 
HPLC standards (purity ≥ 95%), Fluorescein isothiocyanate-dextran (FD4), 
Rhodamine-123 (Rh-123) and glibenclamide (Glib) were purchased from Sigma-
Aldrich with purity ≥ 95%. DMEM (Dulbecco's Modified Eagle Media), GlutaMAX, 
FBS (fetal bovine serum), Penicillin-Streptomycin antibiotic, 0.05% Trypsin/EDTA, 
trypan blue, PBS (Phosphate saline buffer), pH 7.4 were from Gibco. Verapamil 
(Securon I.V. 2.5mg/mL), and vincristine 2mg/mL (Hospira) were both purchased from 
AAH Pharmaceuticals. 
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Plant Material 
Plant materials were either bought in markets or collected from different regions in 
Nigeria in November 2012 by one of the authors (U.F. Ezuruike). Identification of 
collected plant samples collected in the North was done by Mr. Ibrahim Muazzam, an 
ethnobotanist and staff of the Department of Medicinal Plant Research & Traditional 
Medicine, National Institute for Pharmaceutical Research & Development (NIPRD). 
Plant samples collected in the South were verified by staff of the Forestry Research 
Institute of Nigeria (FRIN) in Ibadan. Vouchers were deposited in the Department of 
Pharmaceutical and Biological Chemistry, University College London School of 
Pharmacy, United Kingdom. 
Extraction procedures 
The procedure for extraction of the plant samples (infusion or decoction) was based 
on the traditional use of the plants as described by the respondents (Table 2-3). 
For infusion, 300 ml of boiled distilled water was added to 10g of plant material 
with continuous stirring for 15 minutes on a laboratory hot plate magnetic stirrer 
(IKA Werke Labortechnik). For decoction, 20 g of plant material was heated 
continuously under reflux in a round bottom flask containing 400 ml of distilled water 
for one hour using an Electrothermal 3-in-1 laboratory heating mantle. All extracted 
plant samples were then allowed to stand until cold before filtering with a Buchner 
flask. All the filtered extracts were frozen in round bottom flasks and then freeze 
dried (Edwards Pirani 501 Savant super modulo freeze drier) to obtain the dried 
extract. All dried plant extracts were then stored in 10 ml glass vials at -80°C until 
needed.  
For analyses and cell assays, plant stock concentrations (50 mg/mL) were prepared by 
dissolving crude extracts in bidistilled, microfiltered, aseptic water (MiliQ). 
The solutions were cold sterilised by microfiltration (Millipore disk filters, 0.22 
microns) in a laminar flow cabinet into sterile microcentrifuge tubes. These aliquots 
were at -80°C until further testing. 
Phytochemical analyses 
For phytochemical fingerprinting, chromatograms were obtained in an Agilent 
1100 Series (Gradient Quaternary Pump, Online degasser, Photodiode array 
detector) Software ChemStation. Elution conditions for phytomarkers were as 
described by 
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Giner et al. [20] on a Phenomenex C18 column (250 × 4.6 mm id, 5 μm). Solvent A 
(H2O + Acetic Acid 0.2 %) and B (methanol + Acetic Acid 0.2 % were mixed in 
gradient mode as follows: 0 min 90% A, 0-5 min 80% A, 5-45 min 50% A, 45-55 min 
20% A; flow rate 0.8 mL/min. The injection volume, column temperature, and UV 
wavelength were set at 80 μL, 30°C and 254 nm, respectively. 
Cell lines and cell culture 
HepG2 cells (Sigma-Aldrich) were cultured in MEM medium (GIBCO) supplemented 
with 10% FBS, penicillin (100 U/mL), streptomycin (100 μg/mL). A Caco-2 cell line 
resistant to vincristine (Caco-2 VCR) with enhanced Rh-123 efflux activity due to P-
gp overexpression was established and kindly provided by Dr E. Chieli (University of 
Pisa, Italy). Caco2 VCR cells were cultured in DMEM medium (GIBCO) supplemented 
with 10% FBS, penicillin (100 U/mL), streptomycin (100 μg/mL), 1% non-essential 
aminoacid (NEEA) and 20 μM of Vincristine (Securon ampoules). All cells were kept 
at 37°C in an incubator with a humidified atmosphere of 5%CO2.  
Cell viability assays 
Neutral Red (NR) uptake studies were performed according the protocol detailed by 
Repetto et al. [21]. Briefly, the cells were cultured in 96-well tissue culture plates by 
adding 200μL/well of a suspension of 2 x 104 after 24-hours incubation of Caco-2 cells 
with the plant extracts, media was removed and 100 µL of NR solution (40µg/mL) pre-
warmed at 37° C was added to each well and all plates were placed in the incubator at 
37° C for 2h. The cells were rinsed with 150 µL of PBS and the washing solution 
removed by decanting or gently tapping the plate. 150µL of ‘neutral red extracting’ 
solution (96% ethanol, deionised water, glacial acetic acid; 50%:49%:1%) was added 
to each well of the plate after the washing step. The plate was immediately shaken on a 
microplate shaker (IKA MS3 basic shaker) for at least 10 minutes until the neutral red 
had been completely extracted from the cells and formed a homogenous solution. The 
optical density (O.D.)/absorbance of the extracted neutral red was read out in the plate 
reader (Tecan) at 540nm. The Maximum Non-Toxic Concentration (MNTC) 
was calculated as the concentration of treatment not killing more than 10% of the 
cell population. 
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Determination of glutathione 
This protocol is a modification of enzymatic recycling methodologies reported 
by Allen et al. [22] and Rahman et al. [23]. HepG2 cells (4x104 cells/well) were plated 
out in transparent flat-bottom 96 well plates and incubated for cell at 37°C with 5% 
CO2 for 24 hours. Afterwards, the cells were treated with the plant extracts (MNTC or 
100 µg/mL, whichever is lower) and the 10 µM of the positive control buthionine 
sulphoximine (BSO) incubated for 24 hours at same conditions. Subsequently, the 
medium of each well was aspirated and the wells were washed with 200 μl of PBS. 
Cells were then lysated with Triton X-100 0.1% solution (50μl) and 25 μl of the cell 
solution were transferred to another 96 well plate for further protein analysis. 
The plates were then treated with 25 μl 5%(v/v) sulfosalicylic acid solution and 
25 μl of the solution were aliquoted for analysis. GSH reduced standards at 
concentrations from 100 to 0.78 μM were prepared and 25 μl were added to the plates. 
25 μl of 5% (v/v) sulfosalicylic acid were also added the plate to serve as blank control. 
The glutathione reaction buffer (7.5 mL of sodium phosphate buffer solution, 2mg/mL 
of 2.39mM β-NADPH solution and 1mL of 0.01M DTNB (5,5’-Dithiobis-(2-
Nitrobenzoic Acid) solution) was added to the plates (125 μl) and the absorbances were 
read every 30 seconds for 5 minutes at 405nm. Total GSH concentration in the samples 
was calculated by the following formula: GSH concentration unknown = (GSH ABS ± 
b)/m, where: GSH ABS is the slope (rate of change) of the DTNB absorbance of the 
unknown; m is the slope (the rate of change) of the glutathione standard curve; b is the 
y-intercept of the glutathione standard curve.
Rhodamine-123 uptake assay 
Rhodamine-123 (Rh-123) uptake/efflux assays were conducted as described by Chieli 
et al. [11] with minor modifications. Caco-2 Vincristine-Resistant cells were seeded 
into 96-well plates for 24 hours to allow for attachment. Then, the growth media was 
changed to serum free media. Rh-123 (5 µg/mL) was added to the wells already 
containing MNTC or 100 µg/mL -whichever was lower- of the extracts. 20µM 
verapamil was used as drug reference. After 2 hours incubation, cells were washed 
with 20µM verapamil in PBS to stop P-gp efflux activity. Supernatant was taken 
out and cells lysed with 100 µL of 0.1% Triton X-100 in PBS and the plates were 
placed in the incubator for 15 minutes. 80 µL of the cell lysates was transferred to a 
96-well black 
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plate and the fluorescence intensity in each well measured in a Tecan plate reader (Exc-
485nm, Em-525nm). The cellular accumulation of Rh-123 for each of the extracts was 
expressed as the percentage of the accumulation of Rh-123 in the presence of water 
only. 
Drug In vitro Transport in Caco-2 Monolayers 
The protocol used for this assay is as described in Hubatsch et al [24] with slight 
modifications.  
Preparation of the cell culture: 24-well cell culture polyethylene terephthalate (PET) 
inserts with 0.4 µM pore size and 0.33 cm2 surface area (Millipore-PIHT12R48) pre-
loaded in sterile 24-well plates were used for the transport studies. Caco-2 wild type 
cells from maximally confluent flasks (80- 90%) were trypsinized and then seeded out 
in the apical layer of the permeable filters at a density of 5 x 105 cells/mL in 200µL of
complete media (1 x 105 cells/insert). The filters were pre-wet with 30µL of complete 
media prior to seeding. The basolateral chamber of the inserts was each filled with 1 
mL of complete cell media. The plates were then placed in the incubator overnight (or 
for a maximum of 16 hours) to allow for cell attachment. After the incubation period, 
the medium in the apical layer was replaced with 0.2 mL of fresh complete cell medium 
so as to remove non-adherent cells as well as to prevent the formation of a multilayer. 
Maintenance of the cell culture: Cells were maintained every other day for at least 
21days by carefully aspirating off the media in both the apical and basolateral layers 
and replacing with appropriate volume of fresh medium. The transepithelial electrical 
resistance (TEER) of the monolayer was measured at least once each week with a 
Millicell ERS-1 voltammeter (Millipore) to monitor the integrity of the monolayer. 
Cells were only used for transport experiments if TEER values were > 300 Ω·cm2. This 
was calculated by subtracting the resistance reading from that of a blank filter without 
cells and multiplying by the surface area of the monolayer. Culture media of the cells 
were changed 24 hours prior to the transport experiment to prevent exhaustion of the 
media nutrients. 
Transport and Donor solutions: Hank’s balanced salt solution (HBSS) at pH 7.4 
buffered with 25mM HEPES and 0.35g/l NaHCO3 was prepared as the transport 
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solution. 10 µM glibenclamide alone or with the selected plant extracts at a 
concentration of 50 or 100 µg/mL, depending on the estimated MNTC. The positive 
control consisted on 20µM verapamil added to the transport solution containing 
glibenclamide. The receiver solution was either the HBSS transport solution alone for 
glibenclamide transport alone, or the transport solution with either the extracts or 
verapamil. All donor solutions contained 1mg/mL Fluorescein isothiocyanate-dextran 
(FD4) for monitoring the integrity of the monolayer during the experiment. All 
solutions were sterile filtered with 0.22µm Millipore filters and then pre-warmed at 
37°C before use.  
Transport experiments: The inserts (membrane supports) with the cell monolayers to 
be used for the transport experiment were pre-washed to remove residual medium by 
gently replacing the media with the HBSS transport solution. The washing was done 
under gentle shaking at 60 rpm for 15-20 minutes on a PS-3D laboratory orbital shaker 
(Grant-bio Instruments) within a humidified incubator without CO2 set at 37°C 
(Memmert D-91126). After washing, the TEER of the monolayers was measured prior 
to commencing the transport studies. 
Transport studies were carried out in the apical to basolateral (AP-BL) and basolateral 
to apical (BL-AP) directions. For AP-BL transport studies, the washing solutions were 
gently removed from the inserts and the 24-well plate and replaced with 1mL of the 
appropriate receiver solution in the BL layer and 0.2mL of the appropriate donor 
solution in the AP layer. For BL-AP transport studies, the washing solution was 
replaced with 0.2mL of the appropriate receiver solution in the AP layer and 1 mL of 
the appropriate donor solution in the BL layer. An excess of 200 µL was added to all 
donor solutions when adding them to inserts, which was immediately removed at t = 0 
min and used to estimate C0. Sample withdrawals were carried out from the chamber 
containing the receiver solution at regular time intervals (15, 30, 60, 90 and 120 min) 
by removing 0.5 mL for AP-BL transport and 0.19 mL for BL-AP transport at each 
time point. Immediate replacement of the exact volume withdrawn by the appropriate 
receiver solution was done. The withdrawn samples were placed into microcentrifuge 
tubes and immediately covered and placed on ice to prevent sample evaporation. Care 
was taken during sample withdrawals not to disrupt the monolayer of cells. The culture 
plate with inserts was placed back on the orbital shaker in the incubator in between 
sample withdrawals to maintain sink conditions. 
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Analytical procedures: Two sets of sample analysis were done for the 
withdrawn samples. An aliquot (50µL) from each time interval was used for 
spectrophotometric analysis (Ex-490nm, Em-520nm) of the transported FD4. A 
calibration curve of FD4 was included in each plate and used to estimate the amount 
of FD4 transported at each time point. The remaining withdrawn samples were 
analysed using a Perkin Elmer HPLC equipped with an UV-Vis photodiode array 
detector to measure the amount of glibenclamide transported at each time point. 
The HPLC conditions used for glibenclamide analysis were as follows: stationary 
phase was a Phenomenex Synergy Polar-RP80A column (150 x 4.6 mm, I.D = 4 
µm) column maintained at 30°C. The mobile phase was an isocratic system 
consisting of 40% (A) 25 mM potassium phosphate buffer (pH 4.5) and 60% (B) 
Acetonitrile. The injected volume of sample was 20 µL and the UV-Vis spectrum 
was monitored at 230 nm with glibenclamide eluting at 2 minutes.  
Calculations: the apparent permeability (Papp) of glibenclamide across the 
monolayers was estimated as follows: Papp = dQ/dt (1/AC0); where dQ/dt is change 
in the amount of drug (nM) transported per time, A is the surface area of the insert 
and C0 is the initial concentration of the drug in the donor chamber. 
Statistics 
Raw data were normalised to percentage with respect to controls. Results are 
expressed as the mean ± SD, N ≥ 3. Bars graphs were drawn with Excel (Microsoft). 
Significance of the results was assessed with Instat (GraphPad Software) and 
expressed as * (P<0.05), ** (P<0.01), *** (P<0.001) and **** (P<0.0001). In single 
concentrations studies all treatments were compared to controls using Dunnet 
Multiple t-test. In concentration-dependent studies all values of a treatment were 
compared to each other using Tukey-Kramer Multiple Comparisons Test. 
All numerical data and statistical analyses presented in the graphs are provided in detail 
as Supporting information. 
Abbreviations 
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TABLE 1. Summary of the codes, botanical details, source, extraction and maximum non-toxic concentrations (MNTC) of the selected plant extracts. 
Code Plant name Family Plant Part Source Extract Yield 
(%w/w) 
MNTC 
(24h; µg/mL) 
HepG2 Caco2 
AB Alstonia boonei De Wild. Apocynaceae Stem-bark Mushin herbal 
market
Decoction 5.03 100 100 
AL Anogeissus leiocarpa (DC.) Guill. & Perr. Combretaceae Stem-bark Herbalist in 
Abuja
Decoction 6.21 20 50 
AD Anthocliesta djalonensis A.Chev. Gentianaceae Stem-bark gbede forest Decoction 3.05 5 >100 
AR Aristolochia repens Mill. Aristolochiaceae Stem Mushin herbal 
market
Infusion 18.11 50 >100 
AS Annona senegalensis Pers. Annonaceae Stem-bark Agbede forest Decoction 7.10 50 50 
BF Bridelia ferruginea Benth. Phyllanthaceae Stem-bark Ibadan herbal 
market
Decoction 75.86 50 50 
CF Cassytha filiformis L. Lauraceae Whole plant Ethnobotanist in 
Abuja
Decoction 12.66 100 >100 
CS Cassia sieberiana DC Leguminosae Root gbede_forest Decoction 10.27 50 >100 
DO Daniellia ogea (Harms) Holland Leguminosae Stem-bark Agbede forest Decoction 6.05 50 50 
GL Gongronema latifolium Benth. Apocynaceae Leaves Mushin herbal 
market
Infusion 8.37 100 >100 
ID Isoberlinia doka Craib & Stapf Leguminosae Stem Zaria herbal 
market
Decoction 4.69 100 >100 
KI Khaya ivorensis A.Chev. Meliaceae Stem-bark Mushin herbal 
market
Decoction 7.83 100 >100 
KS Khaya senegalensis (Desv.) A.Juss. Meliaceae Stem-bark Agbede forest Decoction 5.02 1 >100 
MO Moringa oleifera Lam. Moringaceae Leaves Home garden in 
Imo
Infusion 35.54 1 >100 
MW Mondia whitei (Hook.f.) Skeels Apocynaceae Stem Mushin herbal 
market
Infusion 20.24 1 >100 
OG Ocimum gratissimum L. Lamiaceae Leaves Mushin herbal 
market
Infusion 17.04 1 >100 
PN Picralima nitida (Stapf) T.Durand & H.Durand Apocynaceae Seeds Ibadan herbal 
market
Infusion 23.71 100 >100 
RV Rauvolfia vomitoria Afzel. Apocynaceae Stem-bark Ibadan herbal 
market
Decoction 3.9 1 >100 
SD Scoparia dulcis L. Plantaginaceae Whole plant Ethnobotanist in 
Abuja
Decoction 16.35 100 >100 
SG Syzygium guineense (Willd.) DC. Myrtaceae Stem Zaria herbal 
market
Decoction 8.01 5 >100 
SH Strophanthus hispidus DC. Apocynaceae Stem Ib dan herbal 
market
Decoction 12.2 1 >100 
SL Securidaca longipedunculata Fresen. Polygalaceae Root Mushin herbal 
market
Decoction 7.49 10 >100 
TA Terminalia avicennioides Guill&Perr. 
Perr.
Combretaceae Stem Zaria herbal 
market
Decoction 13.25 100 >100 
TB Tapinanthus bangwensis (Engl.&K.Krause) Danser 
K.Krause) Danser 
Loranthaceae Leaves Herbalist in Imo Infusion 32.2 1 >100 
TI Tamarindus indica L. Leguminosae Stem Zaria herbal 
market
Decoction 6.05 20 >100 
VA Vernonia amygdalina Delile Compositae Leaves Home garden in 
Lagos
Infusion 15.54 100 >100 
XA Ximenia Americana L. Olacaceae Stem Zaria herbal 
market
Decoction 11.5 100 >100 
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Table 2 Effects of P-gp inhibitory plant extracts on the Papp values of glibenclamide and FD4 and the change in TEER values after 2 hours transport experiments in Caco-2 monolayers. Results 
show mean ± SD, N ≥ 3. *P<0.05, **P<0.01 according Dunnett Multiple Comparisons Test. 
Sample Direction 
of transport 
% of Initial 
TEER 
Papp Glib 
(x 10-5 cm/s) 
Efflux ratio 
(Glib) 
Papp FD4 
(x 10-6 cm/s) 
Gliblenclamide (10 µM) AP-BL 67 ± 17 2.65 ± 0.13 - 2.38 ± 0.23 - 5.62 ± 0.32 - 
BL-AP 63 ± 20 6.30 ± 0.33 - 5.05 ± 0.51 - 
Glib (10µM) + Verapamil (20 µM)  AP-BL 63 ± 38 4.06 ± 0.23 ** 1.14 ± 0.25 ** - - 
BL-AP 64 ± 11 4.62 ± 0.26 ** - - 
Glib (10µM) + A. senegalensis (50 µg/ml) AP-BL 48 ± 13 2.36 ± 0.14 ns 2.17 ± 0.19 ns 6.20 ± 0.54 ns 
BL-AP 23 ± 7 5.13 ± 0.25 ** 5.64 ± 0.49 ns 
Glib (10µM) + B. ferruginea (50 µg/ml) AP-BL 44 ± 13 1.66 ± 0.08 ** 2.51 ± 0.16 ns 4.90 ± 1.88 ns 
BL-AP 17 ± 6 4.16 ± 0.23 ** 5.42 ± 2.08 ns 
Glib (10µM) + C. filiformis (100 µg/ml) AP-BL 70 ± 28 1.83 ± 0.12 ** 1.60 ± 0.15 ** 2.93 ± 0.38 ns 
BL-AP 49 ± 36 2.93 ± 0.18 ** 2.11 ± 0.28 * 
Glib (10µM) + D. ogea (50 µg/ml) AP-BL 45 ± 31 1.17 ± 0.06 ** 4.97 ± 0.20 ** 4.40 ± 1.86 ns 
BL-AP 23 ± 9 5.82 ± 0.33 ns 3.95 ± 1.67 ns 
Glib (10µM) + K. ivorensis (100 µg/ml) AP-BL 26 ± 9 5.60 ± 0.32 ** 1.19 ± 0.34 ** 0.77 ± 0.09 * 
BL-AP 18 ± 6 6.66 ± 0.36 ns 1.87 ± 0.21 * 
Glib (10µM) + S. guineense (100 µg/ml) AP-BL 53 ± 23 3.38 ± 0.16 ** 1.70 ± 0.23 ** 5.80 ± 1.60 ns 
BL-AP 20 ± 5 5.76 ± 0.29 ns 2.99 ± 0.83 ns 
Glib (10µM) + T. avicennioides (100 µg/ml) AP-BL 25 ± 17 3.09 ± 0.19 * 1.80 ± 0.25 * 9.67 ± 2.59 ns 
BL-AP 19 ± 5 5.56 ± 0.32 * 2.41 ± 0.65 ns 
Glib (10µM) + X. americana (100 µg/ml) AP-BL 28 ± 13 1.37 ± 0.07 ** 1.66 ± 0.10 ** 9.33 ± 3.97 ns 
BL-AP 25 ± 27 2.27 ± 0.12 ** 3.37 ± 1.44 ns 
Figure 1: Intracellular concentration of glutathione in HepG2 cells after treatment with 
either extracts or 10µM buthionide sulfoximine (But) with respect to the Control 
(water). Results show mean ± SD, N ≥ 3. * P<0.05, ** P<0.01, according Dunnett 
Multiple Comparisons Test. Plant codes as per Table 1. 
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Figure 2: Percentage of intracellular Rh-123 concentration in Caco-2 Vincristine-
Resistant cells in the presence of either extracts or 20µM verapamil (Vp) with respect 
to the Control (water). Results are the mean ± SD, N ≥ 3. * P<0.05 and ** P<0.01, 
according Dunnett Multiple Comparisons Test. Plant codes as per Table 1. 
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Figure 3: Dose-dependent inhibition of Intracellular Rh-123 concentration in Caco-2 
Vincristine Resistant cells in the presence of serial dilutions of the extracts with respect 
to the Control (water). Plant codes and maximum non-toxic concentrations (MNTC) as 
per Table 1. Results are the mean ± SD, N = 3. ns P>0.05, * P<0.05, ** P<0.01, 
according Tukey-Kramer Multiple Comparisons Test. 
